天新药业
(603235)
| 流通市值：109.66亿 | | | 总市值：109.66亿 |
| 流通股本：4.38亿 | | | 总股本：4.38亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,309,382,533.34 | 639,757,715.06 | 2,345,041,106.85 | 1,630,945,301.49 |
| 营业总成本 | 963,287,012.87 | 475,317,848.85 | 1,674,686,700.99 | 1,105,745,608.76 |
| 其他经营收益 | | | | |
| 营业利润 | 380,556,074.42 | 176,818,212.43 | 705,313,445.94 | 553,261,896.65 |
| 利润总额 | 380,435,214.86 | 176,748,387.78 | 704,421,981.46 | 551,645,079.81 |
| 净利润 | 319,324,799.01 | 147,003,605.08 | 591,578,911.11 | 460,303,876.13 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 319,324,799.01 | 147,003,605.08 | 591,578,911.11 | 460,303,876.13 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 3,023,559,793.68 | 2,793,314,271.53 | 2,782,809,512.7 | 2,587,926,908.17 |
| 非流动资产: | | | | |
| 非流动资产合计 | 3,417,949,594.2 | 3,461,138,731.52 | 3,406,910,743.67 | 3,346,358,510.84 |
| 资产总计 | 6,441,509,387.88 | 6,254,453,003.05 | 6,189,720,256.37 | 5,934,285,419.01 |
| 流动负债: | | | | |
| 流动负债合计 | 849,680,750.84 | 549,732,122.16 | 635,585,126.35 | 472,604,065.88 |
| 非流动负债: | | | | |
| 非流动负债合计 | 595,330,382.64 | 641,200,166.42 | 637,618,020.63 | 676,439,278.72 |
| 负债合计 | 1,445,011,133.48 | 1,190,932,288.58 | 1,273,203,146.98 | 1,149,043,344.6 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,996,498,254.4 | 5,063,520,714.47 | 4,916,517,109.39 | 4,785,242,074.41 |
| 股东权益合计 | 4,996,498,254.4 | 5,063,520,714.47 | 4,916,517,109.39 | 4,785,242,074.41 |
| 负债和股东权益合计 | 6,441,509,387.88 | 6,254,453,003.05 | 6,189,720,256.37 | 5,934,285,419.01 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,340,339,177.34 | 610,159,256.3 | 2,136,067,479.39 | 1,591,041,137.87 |
| 经营活动现金流出小计 | 956,761,998.2 | 473,272,966.43 | 1,506,704,981.72 | 1,100,490,958.78 |
| 经营活动产生的现金流量净额 | 383,577,179.14 | 136,886,289.87 | 629,362,497.67 | 490,550,179.09 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,212,928,003 | 651,545,252.8 | 5,189,506,955.8 | 3,894,940,838.33 |
| 投资活动现金流出小计 | 1,495,565,052.31 | 1,056,555,197.73 | 5,279,003,982.02 | 4,048,948,704.62 |
| 投资活动产生的现金流量净额 | -282,637,049.31 | -405,009,944.93 | -89,497,026.22 | -154,007,866.29 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 133,620,160.88 | 7,414,058.5 | 276,390,025.38 | 252,193,289.42 |
| 筹资活动现金流出小计 | 81,769,118.34 | 2,462,304.27 | 315,975,770.11 | 302,900,354.65 |
| 筹资活动产生的现金流量净额 | 51,851,042.54 | 4,951,754.23 | -39,585,744.73 | -50,707,065.23 |
| 汇率变动对现金及现金等价物的影响 | -30,636,525.43 | -14,170,073.49 | -8,967,062.68 | 3,384,890.8 |
| 现金及现金等价物净增加额 | 122,154,646.94 | -277,341,974.32 | 491,312,664.04 | 289,220,138.37 |
| 期末现金及现金等价物余额 | 1,691,734,506.79 | 1,292,299,787.54 | 1,569,579,859.85 | 1,367,487,334.18 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 122,154,646.94 | - | 491,312,664.04 | - |